EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier

Margaux Robert, Satabdi Saha iD, Nazli Dizman iD, Michelle Rohlfs, Elizabeth Sirmans, Julie Simon, Rodabe N Amaria, Isabella C Glitza Oliva iD, Hussein A Tawbi, Michael A Davies iD, Alexandra Ikeguchi iD, Karen Basen-Engquist und 10 weitere

Nutrients · 2025

DOI: 10.3390/nu18010040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Margaux Robert und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Melanoma, Patient Reported Outcome Measures, Gastrointestinal Microbiome, Diet. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Melanoma Research Alliance, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Immune checkpoint blockade (ICB) therapies have significantly improved outcomes in metastatic melanoma. However, immune-related adverse events (irAEs) and persistent chronic toxicities (CTs) among this emerging survivor population likely influence different facets of quality of life. This study characterized CT, patient-reported outcomes (PROs), diet, physical activity and gut microbiome features in a cohort of long-term survivors with a history of ICB-treated metastatic melanoma.

Methods

Forty-eight patients with a history of metastatic melanoma who initiated ICB treatment at least 3 years earlier and were not currently on treatment were prospectively enrolled from a melanoma survivorship clinic. Participants completed screening questionnaires for depression, anxiety, diet and physical activity. The gut microbiome was characterized via metagenomic sequencing in a subsample (n = 39). Patients’ clinicopathological characteristics and experience of irAEs (during treatment) and CT (persisting >6 months after completion of therapy) were extracted retrospectively from the medical record.

Results

In the overall cohort, 60% were experiencing CT, while 16% and 20% reported clinically relevant levels of depression and anxiety symptoms, respectively. We observed significant differences in overall gut microbiome composition between survivors with and without CT (p = 0.02). Consumption of fruit and vegetables was inversely associated with anxiety (ρ = 0.3, p = 0.038). Added sugar consumption was correlated with the severity of experienced symptoms (ρ = 0.4, p = 0.003), with pronounced associations across the spectrum of symptoms, including pain, fatigue and shortness of breath (p < 0.05).

Conclusions

These results suggest that CT is experienced by a substantial proportion of ICB-treated metastatic melanoma survivors. Patients experiencing CT also showed distinct microbiome features. However, additional research in prospective settings is needed to confirm these hypotheses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaPatient Reported Outcome MeasuresGastrointestinal MicrobiomeDietImmunotherapyCancer SurvivorsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedAgedQuality of LifeAdultAnxietyProspective StudiesDepressionExercise

Stichwörter der Autor:innen

dietimmunotherapymelanoma survivorsmicrobiomepatient-reported outcomes

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Satabdi Saha, Nazli Dizman, Isabella C Glitza Oliva, Michael A Davies, Alexandra Ikeguchi, Keri Schadler, Xiaotao Zhang, Nadim J Ajami, Christine B Peterson, Carrie R Daniel

Förderung

  • NIH HHS
  • Melanoma Research Alliance
  • NCI NIH HHS
  • MD Anderson Melanoma Moon Shot
  • Andrew Sabin Family Fellowship
  • MD Anderson Melanoma Moon Shots Program
  • MD Anderson NCI Cancer Center
  • the Melanoma Research Alliance

Zitieren

APA

Robert, M., Saha, S., Dizman, N., Rohlfs, M., Sirmans, E., Simon, J., Amaria, R. N., Glitza Oliva, I. C., Tawbi, H. A., Davies, M. A., Ikeguchi, A., Basen-Engquist, K., Schadler, K., Roth, M. E., Song, W., Zhang, X., Ajami, N. J., Cohen, L., Wargo, J. A., …, & Daniel, C. R. (2025). Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier. Nutrients. https://doi.org/10.3390/nu18010040

Vancouver

Robert M, Saha S, Dizman N, Rohlfs M, Sirmans E, Simon J, et al. Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier. Nutrients. 2025. doi:10.3390/nu18010040

BibTeX
@article{Robert2025,
  author = {Robert, Margaux and Saha, Satabdi and Dizman, Nazli and Rohlfs, Michelle and Sirmans, Elizabeth and Simon, Julie and Amaria, Rodabe N and Glitza Oliva, Isabella C and Tawbi, Hussein A and Davies, Michael A and Ikeguchi, Alexandra and Basen-Engquist, Karen and Schadler, Keri and Roth, Michael E and Song, Wenye and Zhang, Xiaotao and Ajami, Nadim J and Cohen, Lorenzo and Wargo, Jennifer A and Peterson, Christine B and McQuade, Jennifer L and Daniel, Carrie R},
  title = {Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier},
  journal = {Nutrients},
  year = {2025},
  doi = {10.3390/nu18010040}
}
Kostenlos starten →